ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) announced projected combined net sales of approximately $1.7 billion by 2028, with NUPLAZID contributing around $1 billion and DAYBUE accounting for roughly $700 million, according to a company statement made at the J.P. Morgan Healthcare Conference.

The company received U.S. FDA approval on December 12, 2025, for DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide for treating Rett syndrome in patients 2 years and older. The product will launch on a limited basis in the first quarter of 2026, with full launch planned for the second quarter.

Acadia expects top-line results from its Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis between August and October 2026. The company estimates remlifanserin represents approximately $4 billion of an $11 billion peak sales opportunity across its pipeline.

The Ministry of Health in Israel approved DAYBUE oral solution for Rett syndrome treatment in adults and pediatric patients 2 years and older weighing at least 9 kg. The company anticipates an opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in the first quarter of 2026.

Top-line results from a Phase 3 study in Japan of trofinetide for Rett syndrome treatment are expected between October 2026 and March 2027. The company plans to initiate five Phase 2 or Phase 3 studies across eight programs and deliver four Phase 2 or Phase 3 readouts by the end of 2027.

NUPLAZID is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, while DAYBUE is approved for treating Rett syndrome in adults and pediatric patients 2 years and older.

You May Also Be Interested In

• Winnebago Industries refinances credit facility, extends maturity to 2031
• Lazard Global Total Return fund declares $0.1534 monthly distribution
• Solowin Holdings marks 10 years, expands into stablecoins and AI